French National Database of Rare Dermatological Cancers (CARADERM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03210935|
Recruitment Status : Recruiting
First Posted : July 7, 2017
Last Update Posted : October 16, 2019
Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes.
CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are :
- to provide epidemiological, clinical and socio-economic characteristics of patients
- to identify new clinical or epidemiological prognostic factors for these rare cancers
- to evaluate the impact of various treatments on outcomes
|Condition or disease|
|Adnexal Tumor of Skin Merkel Cell Carcinoma Advanced Basal Cell Carcinoma Requiring Systemic Treatment|
CARADERM is a French national multidisciplinary project which will prospectively enroll from 37 French centers any patient presenting with Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment or cutaneous adnexal carcinoma.
A structured and centralized database of clinical monitoring of patients will be established. Information captured will include clinical constitutional factors, factors linked to primary carcinoma, factors linked to lymph node involvement, "American Joint Committee on Cancer" (AJCC) stage at inclusion, recurrence patterns, therapeutic interventions (medical, surgical, radiotherapy and palliative strategies) with evaluation of response, date of death, date of latest news.
|Study Type :||Observational|
|Estimated Enrollment :||9000 participants|
|Official Title:||French National Database of Rare Dermatological Cancers: Merkel Cell Carcinoma, Inoperable or Metastatic Basal Cell Carcinoma, Cutaneous Adnexal Carcinomas|
|Actual Study Start Date :||November 24, 2015|
|Estimated Primary Completion Date :||December 31, 2025|
|Estimated Study Completion Date :||December 31, 2025|
|Merkel cell carcinoma|
|Advanced basal cell carcinoma|
|Cutaneous adnexal carcinomas|
- Incidence and natural history of the 3 types of rare skin cancers [ Time Frame: 10 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03210935
|Contact: Laurent MORTIER, MD,PhD||03.20.44.41.93 ext +email@example.com|
|Contact: Benoit Minartfirstname.lastname@example.org|
|Principal Investigator:||Laurent MORTIER, MD,PhD||University Hospital, Lille|